组蛋白甲基转移酶SMYD3在乳腺癌中的表达及其意义

Expression of SMYD3 in breast cancer and its clinical significance

目的探讨组蛋白甲基转移酶SMYD3在乳腺癌的表达情况及其意义。方法运用Westernblot法检测SMYD3在乳腺癌细胞系的表达,并用免疫组织化学S-P法检测SMYD3在67例乳腺癌组织及10例正常乳腺组织中的表达,最后对SMYD3表达与乳腺癌各临床病理指标行Mann-WhitneyU或Kruskal-WallisH检验分析。结果SMYD3在MCF-7、MDA-MB-231、SKBR3和MDA-MB-435s等乳腺癌细胞株中均呈阳性表达,而在正常乳腺组织中均无阳性表达。正常组织与癌性组织之间SMYD3阳性表达的差异有统计学意义(U=130.00,P=0.001)。在乳腺癌组织中,SMYD3的总体阳性率为61.19%。SMYD3阳性表达在年龄,组织病理级别,病理类型,ER、PR、BCL-2、P53表达等亚组间差异均无统计学意义(P值均>0.050),而在淋巴结转移、HER-2表达亚组间差异有统计学意义(P值均<0.001)。结论SMYD3阳性表达可作为判断乳腺癌预后的潜在标记物,并有望成为乳腺癌靶向治疗的新靶点。

Objective To investigate the expression of SET and MYND domain containing protein 3 （SMYD3） in breast cancer and its clinical significance. Methods The expression of SMYD3 in breast cancer cell lines and breast cancer tissues was detected respectively by Western Blot and immunohistochemical SP staining in 67 patients with breast cancer and 10 healthy breasts. The relationship between SMYD3 expression and elinicopathological parameters was analyzed with Mann- Whitney U test or Kruskal-Wallis H test. Results SMYD3 was overexpressed in breast cancer cell lines such as MCF-7, MDA-MB-231, SKBR3 and MDAMB-435s. Likewise, SMYD3 was found to be overexpressed also in breast cancer tissues, with a positive rate of 61. 19% （41/67）. No SMYD3 expression was detected in the 10 normal breast tissues 0.00% （0/10）. There was a statistical difference in positive expression of SMYD3 between breast cancer tissue and normal breast tissue （U= 130.00, P= 0. 001）. There was no statistical difference in positive expression of SMYD3 in age, histopathological grading, pathological types, ER, PR BCI.-2 and P53 expressions between subgroups （all P values 0.05）. But the difference of SMYD3 expression in lymph node metastasis and HER-2 expression was statistically significant （ all P values 〈~ 0. 001）. Conclusions SMYD3 can be used as a potential marker in judging breast cancer. SMYD3 may be a promising target in targeted therapy for breast cancer.